María Jesús
Garrido Cid
Catedrática de Universidad
Publicaciones (58) Publicaciones de María Jesús Garrido Cid
2025
2024
-
Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice
Acta Pharmacologica Sinica
-
Lipid-based nanosystems: the next generation of cancer immune therapy
Journal of Hematology and Oncology, Vol. 17, Núm. 1
2023
-
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling
Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632
2022
-
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
Pharmaceutics, Vol. 14, Núm. 3
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
-
Stealth nanoparticles in oncology: Facing the PEG dilemma
Journal of Controlled Release, Vol. 351, pp. 22-36
2021
-
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
Journal of Nanobiotechnology, Vol. 19, Núm. 1
-
Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration
Frontiers in Pharmacology, Vol. 12
-
Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1
British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285
-
Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors
Cancers, Vol. 13, Núm. 20
2020
-
Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology
Clinical Pharmacokinetics, Vol. 59, Núm. 2, pp. 123-135
-
Modificaciones farmacocinéticas y farmacodinámicas en el anciano
Tratado de medicina geriátrica: fundamentos de la atención sanitaria a los mayores (Elsevier), pp. 72-82
-
Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas
Pharmaceutics, Vol. 12, Núm. 6, pp. 1-16
2019
-
A new immune-nanoplatform for promoting adaptive antitumor immune response
Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25
-
Optimization and in-vitro/in-vivo evaluation of doxorubicin-loaded chitosan-alginate nanoparticles using a melanoma mouse model
International Journal of Pharmaceutics, Vol. 556, pp. 1-8
-
Pharmacokinetic and pharmacodynamic modelling in anaesthesia
Personalized Anaesthesia: Targeting Physiological Systems for Optimal Effect (Cambridge University Press), pp. 14-28
2018
-
Immunoliposomes in clinical oncology: State of the art and future perspectives
Journal of Controlled Release, Vol. 275, pp. 162-176
2017
-
Commentary on Pharmacometrics for Immunotherapy
CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 1, pp. 8-10
-
Comparison of liposomal drug formulations for transdermal iontophoretic drug delivery
European Journal of Pharmaceutical Sciences, Vol. 106, pp. 294-301